User profiles for Senthil K Chinnakannan

Senthil Kumar Chinnakannan

Postdoctoral Scientist, University of Oxford
Verified email at infinitopes.com
Cited by 1437

[HTML][HTML] Antibody testing for COVID-19: A report from the National COVID Scientific Advisory Panel

…, S Bibi, M Carroll, SK Chinnakannan… - Wellcome Open …, 2020 - ncbi.nlm.nih.gov
Background: The COVID-19 pandemic caused> 1 million infections during January-March
2020. There is an urgent need for reliable antibody detection approaches to support diagnosis…

[HTML][HTML] Evaluation of antibody testing for SARS-Cov-2 using ELISA and lateral flow immunoassays

…, JI Bell, T Berry, S Bibi, M Carroll, SK Chinnakannan… - MedRxiv, 2020 - medrxiv.org
Background The SARS-CoV-2 pandemic caused >1 million infections during January-March
2020. There is an urgent need for robust antibody detection approaches to support …

NK cells limit therapeutic vaccine–induced CD8+T cell immunity in a PD-L1–dependent manner

MO Diniz, A Schurich, SK Chinnakannan… - Science Translational …, 2022 - science.org
A better understanding of mechanisms that regulate CD8 + T cell responses to therapeutic
vaccines is needed to develop approaches to enhance vaccine efficacy for chronic viral …

[HTML][HTML] Morbillivirus v proteins exhibit multiple mechanisms to block type 1 and type 2 interferon signalling pathways

SK Chinnakannan, SK Nanda, MD Baron - PloS one, 2013 - journals.plos.org
Morbilliviruses form a closely related group of pathogenic viruses which encode three non-structural
proteins V, W and C in their P gene. Previous studies with rinderpest virus (RPV) …

[HTML][HTML] The design and development of a multi-HBV antigen encoded in chimpanzee adenoviral and modified vaccinia Ankara viral vectors; a novel therapeutic …

SK Chinnakannan, TN Cargill, TA Donnison, MA Ansari… - Vaccines, 2020 - mdpi.com
Chronic hepatitis B virus (HBV) infection affects 257 million people globally. Current
therapies suppress HBV but viral rebound occurs on cessation of therapy; novel therapeutic …

Different functions of the common P/V/W and V-specific domains of rinderpest virus V protein in blocking IFN signalling

SK Chinnakannan, B Holzer… - Journal of General …, 2014 - microbiologyresearch.org
The V proteins of paramyxoviruses are composed of two evolutionarily distinct domains, the
N-terminal 75 % being common to the viral P, V and W proteins, and not highly conserved …

[HTML][HTML] Investigation of IRES Insertion into the Genome of Recombinant MVA as a Translation Enhancer in the Context of Transcript Decapping

NK Alharbi, SK Chinnakannan, SC Gilbert, SJ Draper - PLoS One, 2015 - journals.plos.org
Recombinant modified vaccinia virus Ankara (MVA) has been used to deliver vaccine
candidate antigens against infectious diseases and cancer. MVA is a potent viral vector for …

[PDF][PDF] Scientific Advisory Panel [version 1; peer review: awaiting peer

…, JI Bell, T Berry, S Bibi, M Carroll, SK Chinnakannan… - pdfs.semanticscholar.org
Antibody testing for COVID-19: A report from the National COVID Scientific Advisory Panel[version
1; peer review: awaiting peer Page 1 RESEARCH ARTICLE Antibody testing for …

[PDF][PDF] Antibody testing for COVID-19: A report from the National COVID Scientific Advisory Panel [version 1; peer review: 2

…, JI Bell, T Berry, S Bibi, M Carroll, SK Chinnakannan… - academia.edu
Background: The COVID-19 pandemic caused> 1 million infections during January-March
2020. There is an urgent need for reliable antibody detection approaches to support diagnosis…

[CITATION][C] Optimising delivery of therapeutic hepatitis B vaccines to induce resident memory T cells in the liver

T Cargill, S Narayan, SK Chinnakannan, LN Lee… - Journal of …, 2020 - Elsevier